Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market
Biologic drugs in the U.S. enjoy 12 years of exclusivity before biosimilars can enter. Complex patents, high development costs, and legal delays keep prices high. Here’s how the system works-and why patients pay more than in Europe.
Read more
